The FY2025 (Mar) proxy of Immunovant names 13 peer companies for pay. Among Immunovant and these peers, CEO pay was 5th highest of 7 and total shareholder return was 6th highest of 7.
5th highest of 7in Immunovant and its pay peers, FY2025 (Mar) by CEO pay:
$7.7M$19.2M
6th highest of 7in Immunovant and its pay peers, FY2025 (Mar) by total shareholder return:
$34$524
Pay peer group, FY2025 (Mar) proxy
| Madrigal Pharmaceuticals | ||
| BridgeBio Pharma | ||
| Revolution Medicines | ||
| Cytokinetics | ||
| Xenon Pharmaceuticals | ||
| CRISPR Therapeutics AG | ||
| Apellis Pharmaceuticals | Not disclosed | Not disclosed |
| Arcellx | Not disclosed | Not disclosed |
| Arrowhead Pharmaceuticals | Not disclosed | Not disclosed |
| Biohaven | Not disclosed | Not disclosed |
| Blueprint Medicines | Not disclosed | Not disclosed |
| Nuvalent | Not disclosed | Not disclosed |
| Vaxcyte | Not disclosed | Not disclosed |
13 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.